Rituximab in the treatment of pemphigus

References

• Lever WF. Pemphigus and pemphigoid. A review of the advances made since 1964. J Am Acad Dermatol. 1979;1:2–31.
   Google Scholar
• Thiers BH. Pemphigus. J Am Acad Dermatol. 1981;4:603–605.
   Google Scholar
• Bystryn JC. Autoimmune diseases of the skin. Allergy Proc. 1989;10:393–396.
   Google Scholar
• All about pemphigus. International pemphigus & pemphigoid foundation. 2016 [cited 2016 Jul 3]. Available from: http://www.pemphigus.org/living-with-pemphigus-pemphigoid/all-about-pemphigus-patient-edition/
   Google Scholar
• Amagai M. Pemphigus: autoimmunity to epidermal cell adhesion molecules. Adv Dermatol. 1996;11:319–352. discussion 353.
   Google Scholar
• Chernyavsky A, Chen Y, Wang PH, et al. Pemphigus vulgaris antibodies target the mitochondrial nicotinic acetylcholine receptors that protect keratinocytes from apoptolysis. Int Immunopharmacol. 2015;29:76–80.
   Google Scholar
• Venugopal SS. Murrell DF. Diagnosis and clinical features of pemphigus vulgaris. Dermatol Clin. 2011;29:373–380.
   Google Scholar
• Martin LK, Werth VP, Villaneuva EV, et al. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2011;64:903–908.
   Google Scholar
• Zhao CY, Murrell DF. Pemphigus vulgaris: an evidence-based treatment update. Drugs. 2015;75:271–284.
   Google Scholar
• Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:545–552.
   Google Scholar
• Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772–1779.
   Google Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–7368.
   Google Scholar
• McLaughlin P, Grillo-Lopez A, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 1998;16:2825–2833.
   Google Scholar
• Smolen JS, Keystone EC, Emery P, et al. Working group on the rituximab consensus statement. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:143–150.
   Google Scholar
• Gürcan HM, Keskin DB, Stern JN, et al. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009;9:10–25.
   Google Scholar
• McMillan R, Taylor J, Shephard M, et al. World workshop on oral medicine VI: a systematic review of the treatment of mucocutaneous pemphigus vulgaris. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120:132–142.
   Google Scholar
• Salmanpour R, Shahkar H, Namazi MR, et al. Epidemiology of pemphigus in south-western Iran: a 10-year retrospective study (1991–2000). Int J Dermatol. 2006;45:103–105.
   Google Scholar
• Ruocco V, Ruocco E, Lo Schiavo A, et al. Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies. Clin Dermatol. 2013;31:374–381.
   Google Scholar
• Chan LS. Autoimmune diseases. In: Chan LS, editor. Blistering skin diseases, 1st edn. Washington (DC): Monson publishing; 2009. p. 26–31.
   Google Scholar
• Naseer SY, Gill L, Shah J, et al. Gender-based variability in disease presentation in pemphigus vulgaris. J Drugs Dermatol. 2014;13:1225–1230.
   Google Scholar
• Alpsoy E, Akman-Karakas A, Uzun S. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid. Arch Dermatol Res. 2015;307:291–298.
   Google Scholar
• Leshem YA, Katzenelson V, Yosipovitch G, et al. Autoimmune diseases in patients with pemphigus and their first-degree relatives. Int J Dermatol. 2011;50:827–831.
   Google Scholar
• European dermatology forum. EDF Guidelines. 2016 [cited 2016 Jul 3]. Available from: http://www.euroderm.org/edf/index.php/edf-guidelines/category/5-guidelines-miscellaneous?download=40:guideline-diagnosis-and-treatment-of-autoimmune-bullous-diseases-pemphigus
   Google Scholar
• Amagai M, Tanikawa A, Shimizu T, et al. Committee for guidelines for the management of pemphigus disease. Japanese guidelines for the management of pemphigus. J Dermatol. 2014;41:471–486.
   Google Scholar
• Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58:1043–1046.
   Google Scholar
• Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment–guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29:405–414.
   Google Scholar
• Eming R, Sticherling M, Hofmann SC, et al. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges. 2015;13:833–844.
   Google Scholar
• Johnston KM, Bolbocean C, Connors J, et al. Cost-effectiveness of rituximab in follicular lymphoma. Expert Rev Pharmacoecon Outcomes Res. 2012;12:569–577.
   Google Scholar
• Launois R, Payet S, Saidenberg-Kermanac’h N, et al. Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. Joint Bone Spine. 2008;75:688–695.
   Google Scholar
• Goldstein DM, Gabriel T. Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. Curr Top Med Chem. 2005;5:1017–1029.
   Google Scholar
• Huang A, Madan RK, Levitt J. Future therapies for pemphigus vulgaris: rituximab and beyond. J Am Acad Dermatol. 2016 Apr;74:746–753.
   Google Scholar
• Klein C, Lammens A, Schafer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5:22–33.
   Google Scholar
• Ellebrecht CT, Choi EJ, Allman DM, et al. Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. AMA Dermatol. 2014;150:1331–1335.
   Google Scholar
• Vincent FB, Saulep-Easton D, Figgett WA, et al. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013;24:203–215.
   Google Scholar
• Lenert A, Lenert P. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des Devel Ther. 2015;9:333–347.
   Google Scholar
• Liu Z, Davidson A. BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res. 2011;317:1270–1277.
   Google Scholar
• Davidson A. Targeting BAFF in autoimmunity. Curr Opin Immunol. 2010;22:732–739.
   Google Scholar
• Stohl W. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets. 2014;18:473–489.
   Google Scholar
• Parameswaran R, Lim M, Fei F, et al. Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R. Mol Cancer Ther. 2014;13:1567–1577.
   Google Scholar
• Ellebrecht CT, Bhoj VG, Nace A, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353:179–184.
   Google Scholar
• Rituxan. Professional information. [cited 2016 Jul 3]. Available from: www.drugs.com/pro/rituxan.html
   Google Scholar
• Zambruno G, Borradori L. Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion. J Invest Dermatol. 2008;128:2745–2747.
   Google Scholar
• Leandro MJ, Cambridge G, Ehrenstein MR, et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:613–620.
   Google Scholar
• Currimbhoy S, Zhu V, Dominguez AR, et al. Rituximab in the treatment of 38 patients with Pemphigus with long-term follow-up. J Eur Acad Dermatol Venereol. 2016;30:1050–1052.
   Google Scholar
• Tomsitz D, Stefaniak R, Worm M. Rituximab in patients with recalcitrant autoimmune blistering diseases: experience in a cohort of 22 patients. Br J Dermatol. 2015;172:829–831.
   Google Scholar
• Amber KT, Hertl M. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. J Eur Acad Dermatol Venereol. 2015;29:777–782.
   Google Scholar
• Kanwar AJ, Vinay K, Sawatkar GU, et al. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Br J Dermatol. 2014;170:1341–1349.
   Google Scholar
• Colliou N, Picard D, Caillot F, et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med. 2013;5:175ra30.
   Google Scholar
• Leshem YA, Hodak E, David M, et al. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. JAmAcad Dermatol. 2013;68:404–411.
   Google Scholar
• Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148:1031–1036.
   Google Scholar
• Cianchini G, Lupi F, Masini C, et al. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol. 2012;67:617–622.
   Google Scholar
• Kim JH, Kim YH, Kim MR, et al. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011;165:646–651.
   Google Scholar
• Eming R, Nagel A, Wolff-Franke S, et al. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol. 2008;128:2850–2858.
   Google Scholar
• Mouquet H, Musette P, Gougeon ML, et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol. 2008;128:2859–2869.
   Google Scholar
• Cianchini G, Corona R, Frezzolini A, et al. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol. 2007;143:1033–1038.
   Google Scholar
• Sharma VK, Bhari N, Gupta S, et al. Clinical efficacy of rituximab in the treatment of pemphigus: a retrospective study. Indian J Dermatol Venereol Leprol. 2016;82:389–394.
   Google Scholar
• Ahmed AR, Kaveri S, Spigelman Z. Long-term remissions in recalcitrant pemphigus vulgaris. N Engl J Med. 2015;373:2693–2694.
   Google Scholar
• Feldman RJ, Ahmed AR. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. Expert Rev Clin Immunol. 2011;7:529–541.
   Google Scholar
• Gregoriou S, Efthymiou O, Stefanaki C, et al. Management of pemphigus vulgaris: challenges and solutions. Clin Cosmet Investig Dermatol. 2015;8:521–527.
   Google Scholar
• Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994;15:450–454.
   Google Scholar
• Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol. 2000;27:17–24.
   Google Scholar
• Cragg MS, Walshe CA, Ivanov AO, et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140–174.
   Google Scholar
• Beers SA, Chan CH, French RR, et al. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol. 2010;47:107–114.
   Google Scholar
• Cartron G, Blasco H, Paintaud G, et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol. 2007;62:43–52.
   Google Scholar
• Golay J, Semenzato G, Rambaldi A, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs. 2013;5:826–837.
   Google Scholar
• Beum PV, Kennedy AD, Williams ME, et al. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol. 2006;176:2600–2609.
   Google Scholar
• Boumans MJ, Tak PP. Rituximab treatment in rheumatoid arthritis: how does it work? Arthritis Res Ther. 2009;11:134.
   Google Scholar
• Ahmed AR, Shetty SA. Comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev. 2015;14:323–331.
   Google Scholar
• Wang HH, Liu CW, Li YC, et al. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95:928–932.
   Google Scholar
• Daneshpazhooh M, Zafarmand Sedigh V, Balighi K, et al. Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission. J Am Acad Dermatol. 2016;74:1160–1165.
   Google Scholar
• Leuci S, Levine D, Zhang J, et al. Response in patients with pemphigus vulgaris to rituximab therapy. Basis of the biology of B cells. G Ital Dermatol Venereol. 2009;144:379–409.
   Google Scholar
• Mélet J, Mulleman D, Goupille P, et al. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum. 2013;65:2783–2790.
   Google Scholar
• Hammers CM, Chen J, Lin C, et al. Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years. J Invest Dermatol. 2015;135:742–749.
   Google Scholar
• Daneshpazhooh M, Chams-Davatchi C, Khamesipour A, et al. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity. J Eur Acad Dermatol Venereol. 2007;21:1319–1324.
   Google Scholar
• Schmidt E, Hennig K, Mengede C, et al. Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol. 2009;132:334–341.
   Google Scholar
• Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010;14:E10–E21.
   Google Scholar
• Shetty S, Ahmed AR. Preliminary analysis of mortality associated with rituximab use in autoimmune diseases. Autoimmunity. 2013;46:487–496.
   Google Scholar
• Palazzo E, Yahia SA. Progressive multifocal leukoencephalopathy in autoimmune diseases. Joint Bone Spine. 2012;79:351–355.
   Google Scholar
• Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007;56:3044–3056.
   Google Scholar
• Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function. Immunity. 2015;42:607–612.
   Google Scholar
• Olszewska M, Kolacinska-Strasz Z, Sulej J, et al. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol. 2007;8:85–92.
   Google Scholar
• Gregoriou S, Giatrakou S, Theodoropoulos K, et al. Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial. Dermatology. 2014;228:158–165.
   Google Scholar
• Leshem YA, Gdalevich M, Ziv M, et al. Opportunistic infections in patients with pemphigus. J Am Acad Dermatol. 2014;71:284–292.
   Google Scholar
• Amagai M. Modulating immunity to treat autoimmune disease. N Engl J Med. 2016;375:1487–1489.
   Google Scholar
• Renard D, Cornillet L, Castelnovo G. Myocardial infarction after rituximab infusion. Neuromuscul Disord. 2013;23:599–601.
   Google Scholar
• van Sijl AM, van der Weele W, Nurmohamed MT. Myocardial infarction after rituximab treatment for rheumatoid arthritis: is there a link? Curr Pharm Des. 2014;20:496–499.
   Google Scholar
• Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol. 2000;42:422–427.
   Google Scholar
• Barreto JN, Ice LL, Thompson CA, et al. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy. Am J Hematol. 2016;91:1113–1117.
   Google Scholar
• Besada E, Nossent JC. Should Pneumocystis jiroveci prophylaxis be recommended with rituximab treatment in ANCA-associated vasculitis? Clin Rheumatol. 2013;32:1677–1681.
   Google Scholar